HeartFlow expects FDA go-ahead for imaging-based FFR software any day now
This article was originally published in Clinica
Executive Summary
HeartFlow is expecting US FDA approval for its computed tomography-based coronary fractional flow reserve software (FFRCT) very soon, and a US launch will follow straight after. The firm plans to start with around half a dozen sites, CEO John Stevens told Clinica’s sister publication The Gray Sheet.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.